Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BIOLASE, a leader in dental lasers, reported a 24% revenue increase to $48.5 million for 2022. U.S. laser sales surged by 39%, contributing significantly to this growth. The company's consumable sales grew by 25%, with 84% of U.S. Waterlase sales coming from new customers. Despite the positive results, gross margin decreased to 33% and operating losses widened to $25.3 million, up 54% from 2021. Looking forward, BIOLASE anticipates at least 25% revenue growth in 2023 and aims for positive adjusted EBITDA. The company ended 2022 with $4.2 million in cash, boosted by a January equity raise of $9 million.
BIOLASE, Inc. announced its annual Tequila & Tongue Ties Conference set for April 21-22, 2023, in Scottsdale, AZ. The event aims to educate dental professionals about tethered oral tissues (TOTs) impacting many newborns. Key opinion leaders will share insights on tongue-tie treatments and the use of the company's Waterlase all-tissue laser. The conference will provide hands-on experience and discussions on practice management. BIOLASE emphasizes its commitment to resolving dental issues to enhance patient care.
BIOLASE, Inc. (NASDAQ: BIOL) will release its fourth quarter and full year 2022 financial results on March 28, 2023, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and related corporate developments. Investors can join the call by dialing 888-506-0062 from the U.S. or +1 973-528-0011 internationally, using earnings code 121864. An archived version of the call will be available on the BIOLASE Investor Relations Page along with a phone replay. BIOLASE is a leader in dental lasers, offering over 302 patented technologies for enhanced dental procedures.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
